Synthetic Nanovaccines Against Respiratory Pathogens (SYNARP)
Final rept. 1 Jul 2009-30 Jun 2013
NEBRASKA UNIV MEDICAL CENTER OMAHA
Pagination or Media Count:
The overall goal of this proposal is to develop fully synthetic vaccines against respiratory infections using novel nanotechnology platforms based on safe and degradable adjuvant polymer systems that enhance antigen presentation and stimulate immunity. The proposal focuses on achieving the following specific technical objectives 1 Develop molecular methods for intervention strategies employing novel synthetic nanovaccine platforms encapsulating DNA and proteinpeptide antigens that elicit immune response against influenza H5N1 2 Test the efficacy of nanovaccines-based intervention regimens against influenza H5N1 in animal models. 3 Adopt intervention strategies using most promising nanovaccine platforms to other respiratory infections, such as pulmonary F. tularemia, and test the nanovaccines efficacy in animal models unfunded option. Focusing on respiratory infections, the leading cause of outpatient illness and a major cause of infectious disease hospitalization in U.S. military personnel, has the potential to develop effective, safe and affordable synthetic vaccines.
- Anatomy and Physiology
- Medicine and Medical Research